Exploiting KRAS-mediated metabolic reprogramming as a therapeutic target

被引：0
|
作者：
Sanne Bootsma
Sanne M. van Neerven
Louis Vermeulen
机构：
[1] Amsterdam University Medical Centers,Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology and Metabolism
[2] Oncode Institute Amsterdam,undefined
来源：
Nature Genetics | 2021年 / 53卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Half of all colorectal cancers bear KRAS-activating mutations that affect the metabolic dependencies of cancer cells and drive resistance to commonly used drugs. A new study provides insights into KRAS-driven metabolic rewiring and identifies a new therapeutic target for KRAS-mutant cancers.
引用
收藏
页码：9 / 10
页数：1
相关论文
共 50 条
  • [21] Metabolic reprogramming of osteoclasts represents a therapeutic target during the treatment of osteoporosis
    Taubmann, Jule
    Krishnacoumar, Brenda
    Boehm, Christina
    Faas, Maria
    Mueller, Dorothea I. H.
    Adam, Susanne
    Stoll, Cornelia
    Boettcher, Martin
    Mougiakakos, Dimitrios
    Sonnewald, Uwe
    Hofmann, Joerg
    Schett, Georg
    Kroenke, Gerhard
    Scholtysek, Carina
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [22] Metabolic reprogramming of osteoclasts represents a therapeutic target during the treatment of osteoporosis
    Jule Taubmann
    Brenda Krishnacoumar
    Christina Böhm
    Maria Faas
    Dorothea I. H. Müller
    Susanne Adam
    Cornelia Stoll
    Martin Böttcher
    Dimitrios Mougiakakos
    Uwe Sonnewald
    Jörg Hofmann
    Georg Schett
    Gerhard Krönke
    Carina Scholtysek
    Scientific Reports, 10
  • [23] Metabolic reprogramming as a novel therapeutic target for Coxsackievirus B3
    Kuk, Myeong Uk
    Ga, Yun Ji
    Kim, Ye Jin
    Park, Ji Yun
    Song, Eun Seon
    Lee, Haneur
    Lee, Yun Haeng
    Ko, Gahyun
    Kim, Jae Kwang
    Yeh, Jung-Yong
    Kwon, Hyung Wook
    Byun, Youngjoo
    Park, Joon Tae
    ANIMAL CELLS AND SYSTEMS, 2022, 26 (06) : 275 - 282
  • [24] Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours
    H Yurugi
    F Marini
    C Weber
    K David
    Q Zhao
    H Binder
    L Désaubry
    K Rajalingam
    Oncogene, 2017, 36 : 4778 - 4789
  • [25] RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer
    R Kang
    W Hou
    Q Zhang
    R Chen
    Y J Lee
    D L Bartlett
    M T Lotze
    D Tang
    H J Zeh
    Cell Death & Disease, 2014, 5 : e1480 - e1480
  • [26] Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours
    Yurugi, H.
    Marini, F.
    Weber, C.
    David, K.
    Zhao, Q.
    Binder, H.
    Desaubry, L.
    Rajalingam, K.
    ONCOGENE, 2017, 36 (33) : 4778 - 4789
  • [27] Metabolic reprogramming in KRAS-mutant cancers: Proven targetable vulnerabilities and potential therapeutic strategies
    Wu, Ruilin
    Zhu, Hong
    He, Qiaojun
    Yuan, Tao
    Yang, Bo
    DRUG DISCOVERY TODAY, 2024, 29 (12)
  • [28] Loss of activating transcription factor 3 prevents KRAS-mediated pancreatic cancer
    Azizi, Nawab
    Toma, Jelena
    Martin, Mickenzie
    Khalid, Muhammad Faran
    Mousavi, Fatemeh
    Win, Phyo Wei
    Borrello, Maria Teresa
    Steele, Nina
    Shi, Jiaqi
    di Magliano, Marina Pasca
    Pin, Christopher L.
    ONCOGENE, 2021, 40 (17) : 3118 - 3135
  • [29] PDK4-mediated metabolic reprogramming is a potential therapeutic target for neovascular age-related macular degeneration
    Kim, Juhee
    Jeon, Yujin
    Son, Jinyoung
    Pagire, Haushabhau S.
    Pagire, Suvarna H.
    Ahn, Jin Hee
    Uemura, Akiyoshi
    Lee, In-Kyu
    Park, Sungmi
    Park, Dong Ho
    CELL DEATH & DISEASE, 2024, 15 (08):
  • [30] Activating transcription factor 3 promotes KRAS-mediated pancreatic ductal adenocarcinoma
    Martin, Mickenzie B.
    Shen, Ye
    Pin, Christopher
    CANCER RESEARCH, 2022, 82 (22) : 36 - 36
12345